Circulating Cell-Free DNA Conference – 2016

Cambridge Healthtech Institute’s Third Annual Circulating Cell-Free DNA Clinical Directions and Emerging Avenues for Early Detection March 10-11, 2016 | Hilton San Francisco Union Square | San Francisco, CA Part of the 23rd International Molecular Medicine Tri-Conference Preliminary Agenda | Registration & Pricing

 

Circulating cell-free DNA (cfDNA) currently allows for minimal residual disease detection and treatment monitoring with new clinical data emerging regularly. However, as technology evolves and assays increase in sensitivity, the possibility of earlier detection will become more of a reality. At Cambridge Healthtech Institute’s Third Annual Circulating Cell-Free DNA, leading researchers from academia and industry will come together to address advances as well as existing challenges in this rapidly growing field. This year’s event will place emphasis on early detection, clinical validation of assay sensitivity and specificity, and establishing standards for cfDNA.

CLINICAL VALIDATION OF ASSAY SENSITIVITY AND SPECIFICITY

KEYNOTE: Deep Sequencing of Circulating Tumor DNA for Personalized Cancer Detection and Monitoring
Maximilian Diehn, M.D., Ph.D., Assistant Professor, Radiation Oncology, Stanford University

Clinical Applications of an NGS Assay for Ultrasensitive Measurement of ctDNA
Abhijit Patel, M.D., Ph.D., Assistant Professor, Yale University School of Medicine

Assay Characterization for Clinical Applications
Rebecca Leary, Ph.D., Lab Head and Research Investigator, Genomics Group, Next Generation Diagnostics, Novartis

CLINICAL TRIAL DATA

Pretreatment Assessment and Serial Monitoring of EGFR Mutations from NSCLC Patients Treated with Rociletinib (CO-1686)
Chris Karlovich, Ph.D., Principal Scientist, Molecular Diagnostics, Clovis Oncology

Monitoring Cancer through the Blood
Cloud P. Paweletz, Ph.D., Head, Translational Research Laboratory; Biomarker Lead, Belfer Institute for Applied Cancer Science, Dana Farber Cancer Institute

Pharmacodynamic Assessment of Drug Response by Monitoring Mutational Load in Urinary Circulating Tumor DNA
Mark G. Erlander, Ph.D., CSO, Trovagene

APPLICABILITY OF CFDNA IN EARLY STAGE DISEASE

Application of Tumor-Derived DNA in the Management of Individuals with Cancer
Chetan Bettegowda, M.D., Ph.D., Assistant Professor, Neurological Surgery, Johns Hopkins University School of Medicine

Glypican-1 for Identification of Cancer Exosomes and Early Detection of Pancreatic Cancer
Raghu Kalluri, M.D., Ph.D., Chair, Cancer Biology, MD Anderson Cancer Center

PANEL DISCUSSION: Clinical Implementation of cfDNA
Moderator to be Announced
Panelists: Sabita Sankar, Ph.D., Director, Business Development, Biodesix
Abhijit Patel, M.D., Ph.D., Assistant Professor, Yale University School of Medicine
Cloud P. Paweletz, Ph.D., Head, Translational Research Laboratory; Biomarker Lead, Belfer Institute for Applied Cancer Science, Dana Farber Cancer Institute

ASSESSMENT OF CFDNA TECHNOLOGIES

An Ultra-Accurate System for Cancer Mutation Detection in Circulating Cell-Free DNA from Plasma
Grace Zhao, Ph.D., Co-Founder and Director of Research, AccuraGen

Multipanel Massive Parallel Sequencing cfDNA in Monitoring Cutaneous Melanoma Progression
Dave S.B. Hoon, Ph.D., Director, Molecular Oncology and Sequencing Center, John Wayne Cancer Institute, Providence Health Care

ESTABLISHING STANDARDS FOR CFDNA

Standardization of Plasma Genotyping Prior to Routine Clinical Use
Adrian G. Sacher, M.D., Research Fellow, Medicine, Dana Farber Cancer Institute

Quality Assessment of Cell-Free DNA to Guide Downstream Molecular Analyses
Muhammed Murtaza, Research Assistant Professor, Co-Leader, Center for Non-Invasive Diagnostics, Translational Genomics Research Institute